US Patent

US10919881 — Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan

Composition of Matter · Assigned to Idorsia Pharmaceuticals Ltd · Expires 2038-02-26 · 12y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects novel crystalline forms of the drug aprocitentan, a 4-pyrimidinesulfamide derivative, and their use as endothelin receptor antagonists.

USPTO Abstract

The present invention concerns novel crystalline forms of {5-(4-bromo-phenyl)-6 [2 (5 bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as endothelin receptor antagonists. It also relates to new uses of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, either alone or in combination with other active ingredients or therapeutic agents.

Drugs covered by this patent

Patent Metadata

Patent number
US10919881
Jurisdiction
US
Classification
Composition of Matter
Expires
2038-02-26
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Idorsia Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.